Designing selective COX-2 inhibitors: Molecular modeling approaches

Current Opinion in Drug Discovery and Development

Volumn 5, Issue 4, 2002, Pages 550-561

  Trummlitz, Guenter ^a   Van Ryn, Joanne ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

COX 2 inhibitor; Cyclooxygenase(molecular modeling; Molecular surface; NSAID; Virtual screening; Visualization; X ray

Indexed keywords

4 [5 (4 BROMOPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; 5 (3,5 DI TERT BUTYL 4 HYDROXYBENZYLIDENE) 2 METHOXYIMINO 4 THIAZOLONE; 5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; 5 (4 FLUOROPHENYL) 1 [(4 METHYLSULFONYL)PHENYL] 3 TRIFLUOROMETHYLPYRAZOLE; 5 BROMO 2 (4 FLUOROPHENYL) 3 (4 METHYLSULFONYLPHENYL)THIOPHENE; 6 (2,4 DIFLUOROPHENYLTHIO) 5 METHANESULFONAMIDO 1 INDANONE; ALCLOFENAC; CELECOXIB; CS 502; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETODOLAC; FLOSULIDE; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; INDOPROFEN; LUMIRACOXIB; MECLOFENAMIC ACID; MELOXICAM; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; ROFECOXIB; SUPROFEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALDECOXIB; ZOMEPIRAC; CYCLOOXYGENASE 2; ISOENZYME; MEMBRANE PROTEIN; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS2 PROTEIN, HUMAN;

ALGORITHM; DRUG DESIGN; DRUG SELECTIVITY; DRUG SENSITIVITY; ENZYME SUBSTRATE COMPLEX; MOLECULAR MODEL; REVIEW; SITE DIRECTED MUTAGENESIS; STRUCTURE ACTIVITY RELATION; SURFACE PROPERTY; X RAY CRYSTALLOGRAPHY; ANIMAL; CHEMICAL STRUCTURE; DRUG ANTAGONISM; HUMAN; METABOLISM; METHODOLOGY; PHARMACEUTICS; SYNTHESIS;

ANIMALS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; MODELS, MOLECULAR; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; TECHNOLOGY, PHARMACEUTICAL;

EID: 0036653095     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (90)

1. Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL: Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA (1991) 88(7):2692-2696.
2. Kujubu DA, Fletcher BS, Vamum BC, Lim RW, Herschman HR: TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem (1991) 266(20):12866-12872.
3. O'Banion MK, Sadowski HB, Winn V, Young DA: A serumand glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. J Biol Chem (1991) 266(34):23261-23267.
4. Vane JR: Towards a better aspirin. Nature (1994) 367(6460):215-216.
5. National Institute of Clinical Excellence: Guidance on the use of cyclo-oxygenase (COX) II selective inhibitors, celecoxib, rofecoxib, meloxicam and etodolac for osteoarthritis and rheumatoid arthritis. Technology Appraisal No. 27 (2001). http://www.satoweb.org/download/coxiifullguidance.pdf
6. Picot D, Loll PJ, Garavito RM: The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature (1994) 367(6460):243-249.
7. Luong C, Miller A, Barnett J, Chow J, Ramesha C, Browner MF: Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nat Struct Biol (1996) 3(11)):927-933.
8. Kurumbail RG, Stevens AM, Gierse JK, McDonald JJ, Stegeman RA, Pak JY, Gildehaus D, Miyashiro JM, Penning TD, Seibert K, Isakson PC, Stallings WC: Structural basis for selective inhibition of cyclooxygenase-2 by antiinflammatory agents. Nature (1996) 384(6610):644-648.
9. Garavito RM: Prostaglandin endoperoxide H2 synthases-1 and -2. In: Handbook of Metalloproteins. Messerschmidt A, Huber R, Poulos T, Wieghardt K (Eds), John Wiley & Sons Ltd, Chichester, UK (2001):245-263.
10. Kurumbail RG, Kiefer JR, Mamett LJ: Cyclooxygenase enzymes: Catalysis and inhibition. Curr Opin Struct Biol (2001) 11(6):752-760.
11. Smith WL, DeWitt DL, Garavito RM: Cyclooxygenases: Structural, cellular, and molecular biology. Annu Rev Biochem (2000) 69:145-182.
12. 2 synthase-1. Adv Prostaglandin Thromboxane Leukot Res (1995) 23:99-103.
13. 2 synthase. Nat Struct Biol (1995) 2(8):637-643.
14. 2 synthase cyclooxygenase active site. Biochemistry (1996) 35(23):7330-7340.
15. 2 synthase: Time-dependent and time-independent inhibitors elicit identical enzyme conformations. Biochemistry (2001) 40(17):5172-5180. The X-ray structures of COX-1 with two competitive (ibuprofen and the methylester of flurbiprofen) and two slow, tight-binding inhibitors (aceclofenac and flurbiprofen) are reported. All four inhibitors bind at the same site with very little change in the conformation of COX-1 residues. These results demonstrate that the observed time-dependent kinetics of some NSAIDs do not rely on global conformational changes in the COX isoenzymes.
16. 2.
17. Thuresson ED, Malkowski MG, Lakkides KM, Rieke CJ, Mulichak AM, Ginell SL, Garavito RM, Smith WL: Mutational and X-ray crystallographic analysis of the interaction of dihomo-γ-linolenic acid with prostaglandin endoperoxide H syntheses. J Biol Chem (2001) 276(13):10358-10365.
18. Malkowski MG, Thuresson ED, Lakkides KM, Rieke CJ, Micielli R, Smith WL, Garavito RM: Structure of eicosapentaenoic and linoleic acids in the cyclooxygenase site of prostaglandin endoperoxide H synthase-1. J Biol Chem (2001) 276(40):37547-37555.
19. Kiefer JR, Pawlitz JL, Moreland KT, Stegeman RA, Hood WF, Gierse JK, Stevens AM, Goodwin DC, Rowlinson SW, Mamett LJ, Stallings WC, Kurumbail RG: Structural insights into the stereochemistry of the cyclooxygenase reaction. Nature (2000) 405(6782):97-101.
20. Copeland RA, Williams JM, Giannaras J, Numberg S, Covington M, Pinto D, Pick S, Trzaskos JM: Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase. Proc Natl Acad Sci USA (1994) 91(23):11202-11206.
21. Walker MC, Kurumbail RG, Kiefer JR, Moreland KT, Koboldt CM, Isakson PC, Seibert K, Gierse JK: A three-step kinetic mechanism for selective inhibition of cyclo-oxygenase-2 by diarylheterocyclic inhibitors. Biochem J (2001) 357(3):709-718.
22. Llorens O, Perez JJ, Palomer A, Mauleon D: Structural basis of the dynamic mechanism of ligand binding to cyclooxygenase. Bioorg Med Chem Lett (1999) 9(19):2779-2784.
23. 2 synthase-1. Arch Biochem Biophys (2000) 380(1):39-45.
24. Discover: Accelrys Inc, San Diego, CA, USA. http.//www.accelrys.com/insight/Discover.html
25. Rowlinson SW, Crews BC, Lanzo CA, Marnett LJ: The binding of arachidonic acid in the cyclooxygenase active site of mouse prostaglandin endoperoxide synthase-2 (COX-2). A putative L-shaped binding conformation utilizing the top channel region. J Biol Chem (1999) 274(33):23305-23310.
26. Thuresson ED, Lakkides KM, Rieke CJ, Sun Y, Wingerd BA, Micielli R, Mulichak AM, Malkowski MG, Garavito RM, Smith WL: Prostaglandin endoperoxide H synthase-1: The functions of cyclooxygenase active site residues in the binding, positioning, and oxygenation of arachidonic acid. J Biol Chem (2001) 278(13):10347-10357. The functions of individual amino acid residues within the cyclooxygenase active site of COX-1 in the binding and the activity of AA are studied using an extensive set of site-directed variants of COX-1. The authors identified five categories of amino acids with different functions in the COX catalysis.
27. Sack JS: CHAIN - A crystallographic modeling program. J Mol Graphics (1988) 6:224-225.
28. Schneider C, Boeglin WE, Prusakiewicz JJ, Rowlinson SW, Mamett LJ, Samel N, Brash AR: Control of prostaglandin stereochemistry at the 15-carbon by cyclooxygenases-1 and -2. A critical role for serine 530 and valine 349. J Biol Chem (2002) 277(1):478-485.
29. Ringbom T, Huss U, Stenholm A, Flock S, Skattebol L, Perera P, Bohlin L: COX-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod (2001) 64(6):745-749.
30. Kozak KR, Crews BC, Ray JL, Tai HH, Morrow JD, Mamett LJ: Metabolism of prostaglandin glycerol esters and prostaglandin ethanolamides in vitro and in vivo. J Biol Chem (2001) 276(40):36993-36998.
31. Kozak KR, Prusakiewicz JJ, Rowlinson SW, Schneider C, Mamett LJ: Amino acid determinants in cyclooxygenase-2 oxygenation of the endocannabinoid 2-arachidonylglycerol. J Biol Chem (2001) 276(32):30072-30077.
32. Kalgutkar AS, Crews BC, Rowlinson SW, Garner C, Seibert K, Mamett LJ: Aspirin-like molecules that covalently inactivate cyclooxygenase-2. Science (1998) 280(5367):1268-1270.
33. Amber Home Page: University of California, San Francisco, CA, USA. http://www.amber.ucsf.edu/amber/amber.html
34. Bayly CI, Black WC, Leger S, Ouimet N, Ouellet M, Percival MD: Structure-based design of COX-2 selectivity into flurbiprofen. Bioorg Med Chem Lett (1999) 9(3):307-312.
35. Vane JR, Botting RM: Formation and actions of prostaglandins and inhibition of their synthesis. In: Therapeutic Roles of Selective COX-2 Inhibitors. Vane JR, Botting RM (Eds), William Harvey Press, London, UK (2001):147.
36. Browner MF: The structure of human cyclooxygenase-2 and selective inhibitors. In: Selective COX-2 Inhibitors Pharmacology, Clinical Effects and Therapeutic Potential. Vane JR, Botting J (Eds), Kluwer Academic Publishers, Dordrecht, Germany/Boston, MA, USA/London, UK (1998):1926.
37. So OY, Scarafia LE, Mak AY, Callan OH, Swinney DC: The dynamics of prostaglandin H synthases. Studies with prostaglandin H synthase 2 Y355F unmask mechanisms of time-dependent inhibition and allosteric activation. J Biol Chem (1998) 273(10):5801-5807.
38. Kalgutkar AS, Crews BC, Rowlinson SW, Mamett AB, Kozak KR, Remmel RP, Mamett LJ: Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: Facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors. Proc Natl Acad Sci USA (2000) 97(2):925-930.
39. Kalgutkar AS, Zhao Z: Discovery and design of selective cyclooxygenase-2 inhibitors as non-ulcerogenic, antiinflammatory drugs with potential utility as anti-cancer agents. Curr Drug Targets (2001) 2(1):79-106.
40. Molecular Discovery Ltd, Oxford, UK. http://www.moldiscovery.com/manual/index.html
41. Palomer A, Perez JJ, Navea S, Llorens O, Pascual J, Garcia L, Mauleon D: Modeling cyclooxygenase inhibition. Implication of active site hydration on the selectivity of ketoprofen analogues. J Med Chem (2000) 43(11):2280-2284.
42. Olgen S, Akaho E, Nebioglu D: Synthesis and receptor docking studies of N-substituted indole-2-carboxylic acid esters as a search for COX-2 selective enzyme inhibitors. Eur J Med Chem (2001) 36(9):747-770.
43. Agudoawu S, Li H, Habeeb AG, Rao PNP, Suresh MR, Knaus EE: Design and syntheses of methyl 2-methyl-2-[2-(4-benzoyl-5-phenyl-7-halo-2-azabicyclo[4.1.0]hept-3-ene)] acetates: Novel inhibitors of cyclooxygenase-2 (COX-2) with analgesic antiinflammatory activity. Drug Dev Res (2000) 49(2):75-84.
44. Kothekar V, Sahi S, Srinivasan M: Computer simulation of the interaction of non-steroidal anti-inflammatory drugs: Indoprofen and NS398 with cyclooxygenase. J Biomol Struct Dyn (1999) 16(4):901-915.
45. Lazer ES, Miao CK, Cywin CL, Sorcek R, Wong HC, Meng Z, Potocki I, Hoermann MA, Snow RJ, Tschantz MA, Kelly TA, McNeil DW, Coutts SJ, Churchill L, Graham AG, David E, Grob PM, Engel W, Meier H, Trummlitz G: Effect of structural modification of enol-caboxamide-type nonsteroidal antiinflammatory drug on COX-2/COX-1 selectivity. J Med Chem (1997) 40(6):980-989.
46. 518 in COX-2, allowing meloxicam to occupy the extra space at the top of the COX channel
47. Kothekar V, Sahi S, Srinivasan M, Mohan A, Mishra J: Recognition of cyclooxygenase-2 (COX-2) active site by NSAIDs: A computer modelling study. Indian J Biochem Biophys (2001) 38(1-2):56-63.
48. Luger P, Daneck K, Engel W, Trummlitz G, Wagner K: Structure and physicochemical properties of meloxicam, a new NSAID. Eur J Pharm Sci (1996) 4(3):175-187.
49. Fabiola GF, Pattabhi V, Nagarajan K: Structural basis for selective inhibition of COX-2 by nimesulide. Bioorg Med Chem (1998) 6(12):2337-2344.
50. Garcia-Nieto R, Perez C, Gago F: Automated docking and molecular dynamics simulations of nimesulide in the cyclooxygenase active site of human prostaglandin prostagiandinendoperoxide synthase-2 (COX-2). J Comput Aided Mol Des (2000) 14(2):147-160. Two alternative binding modes are proposed for nimesulide.
51. The Official DOCK WWW Page: Molecular Design Institute, University of California, San Francisco, CA, USA. http://www.cmpharm.ucsf.edu/kuntz/dock.html
52. AutoDock, Automated Docking of Flexible Ligands to Macromolecules: The Scripps Research Instituite, La Jolla, CA, USA. http://www.scripps.edu/pub/olson-web/doc/autodock/index.html
53. Mamett LJ, Rowlinson SW, Goodwin DC, Kalgutkar AS, Lanzo CA: Arachidonic acid oxygenation by COX-1 and COX-2. J Biol Chem (1999) 274(33):22903-22906.
54. Greig GM, Francis DA, Falgueyret JP, Ouellet M, Percival MD, Roy P, Bayly C, Mancini JA, O'Neill GP: The interaction of arginine 106 of human prostaglandin G/H synthase-2 with inhibitors is not a universal component of inhibition mediated by nonsteroidal anti-inflammatory drugs. Mol Pharmacol (1997) 52(5):829-838.
55. Prasit P, Riendeau D, Chan CC: Discovery of rofecoxib. In: Therapeutic Roles of Selective COX-2 Inhibitors. Vane JR, Botting J (Eds), William Harvey Press, London, UK (2001):60-75.
56. Gans KR, Galbraith W, Roman RJ, Haber SB, Kerr JS, Schmidt WK, Smith C, Hewes WE, Ackerman NR: Anti-inflammatory and safety profile of DuP 697, a novel orally effective prostaglandin synthesis inhibitor. J Pharmacol Exp Ther (1990) 254:180-187.
57. 523→Val mutation. J Biol Chem (1997) 272(14):9280-9286.
58. Guo Q, Wang LH, Ruan KH, Kulmacz RJ: Role of Val509 in time-dependent inhibition of human prostaglandin H synthase-2 cyclooxygenase activity by isoform-selective agents. J Biol Chem (1996) 271(32):19134-19139.
59. Gierse JK, McDonald JJ, Hauser SD, Rangwala SH, Koboldt CM, Seibert K: A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors. J Biol Chem (1996) 271(26):15810-15814.
60. 523 in COX-1 has been identified as the key contributor to the COX-2 selectivity of celecoxib.
61. Price MLP, Jorgensen WL: Analysis of binding affinities for celecoxib analogues with COX-1 and COX-2 from combined docking and Monte Carlo simulations and insight into the COX-2/COX-1 selectivity. J Am Chem Soc (2000) 122(39):9455-9466. Binding affinities for celecoxib analogs with COX-1 and COX-2 are explored and the binding conformation of the phenylsulfonamide moiety is clarified. This study demonstrates the presence of the side pocket in COX-1.
62. Jorgensen WL, van Hom WP, Price MCP: MATADOR, Version 1.0. Yale University, New Haven, CT, USA (1999).
63. MCPRO: Yale University, New Haven, CT, USA. http://zarb.chem.yale.edu/products/mcpro/index.shtml
64. SYBYL/Base: Tripos Inc, St Louis, MO, USA. http://www.tripos.com/software/sybase_print.html
65. Chavatte P, Yous S, Marot C, Baurin N, Lesieur D: Three-dimensional quantitative structure-activity relationships of cyclo-oxygenase-2 (COX-2) inhibitors: A comparative molecular field analysis. J Med Chem (2001) 44(20):3223-3230.
66. Bosch J, Roca T, Catena JL, Llorens O, Perez JJ, Lagunas C, Femandez AG, Miquel I, Femandez-Serrat A, Farrerons C: Synthesis and biological evaluation of 1,3,4-triaryl-3-pyrrolin-2-ones, a new class of selective cyclooxygenase-2 inhibitors. Bioorg Med Chem Lett (2000) 10(15):1745-1748.
67. Habeeb AG, Praveen Rao NP, Knaus EE: Design and syntheses of diarylisoxazoles: Novel inhibitors of cyclooxygenase-2 (COX-2) with analgesic-antiinflammatory activity. Drug Dev Res (2000) 51(4):273-286.
68. Habeeb AG, Praveen Rao NP, Knaus EE: Design and synthesis of 4,5-diphenyl-4-isoxazolines: Novel inhibitors of cyclooxygenase-2 with analgesic and antiinflammatory activity. J Med Chem (2001) 44(18):2921-2927.
69. Habeeb AG, Praveen Rao NP, Knaus EE: Design and synthesis of celecoxib and rofecoxib analogues as selective cyclooxygenase-2 (COX-2) inhibitors: Replacement of sulfonamide and methylsulfonyl pharmacophores by an azido bioisostere. J Med Chem (2001) 44(18):3039-3042.
70. Song Y, Connor DT, Doubleday R, Sorenson RJ, Sercel AD, Unangst PC, Roth BD, Gilbertsen RB, Chan K, Schrier DJ, Guglietta A, Bomemeier DA, Dyer RD: Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 1.Thiazolone and oxazolone series. J Med Chem (1999) 42(7):1151-1160.
71. Song Y, Connor DT, Sercel AD, Sorenson RJ, Doubleday R, Unangst PC, Roth BD, Beylin VG, Gilbertsen RB, Chan K, Schrier DJ, Guglietta A, Bomemeier DA, Dyer RD: Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 2. 1,3,4- and 1,2,4-thiadiazole series. J Med Chem (1999) 42(7):1161-1169.
72. Kothekar V, Sahi S, Mishra J: Enzyme selectivity of new cyclooxygenase-2/5 lipoxygenase inhibitors using molecular modeling approach. Indian J Biochem Biophys (2000) 37(2):86-96.
73. Suh YG, Kim YH, Park MH, Choi YH, Lee HK, Moon JY, Min KH, Shin DY, Jung JK, Park OH, Jeon RO, Park HS, Kang SA: Pimarane cyclooxygenase 2 (COX-2) inhibitor and its structure-activity relationship. Bioorg Med Chem Lett (2001) 11(4):559-562.
74. Pouplana R, Lozano JJ, Ruiz J: Molecular modelling of the differential interaction between several non-steroidal antiinflammatory drugs and human prostaglandin endoperoxide H synthase-2 (h-PGHS-2). J Mol Graphics Model (2002) 20(4):329-343.
75. Palomer A, Pascual J, Cabré M, Borràs L, González G, Aparici M, Carabaza A, Cabré F, García ML, Mauleón D: Structure-based design of cyclooxygenase-2 selectivity into ketoprofen. Bioorg Med Chem Lett (2002) 12:533-537.
76. Brickmann J, Exner TE, Keil M, Marhöfer RJ: Molecular graphics - trends and perspectives. J Mol Model (2000) 6(2):328-340. The principles of molecular graphics, including the representations of surface topography, local hydrophobicity and flexibility on enzyme surfaces are presented and future trends discussed.
77. Exner T, Keil M, Moeckel G, Brickmann J: Identification of substrate channels and protein cavities. J Mol Model (1998) 4(10):340-343. A grid-based algorithm is presented for identifying and displaying channels and cavities in protein structures.
78. MOLCAD: Tripos Inc, St Louis, MO, USA. http://www.tripos.com/software/molcad.html
79. Heiden W, Moeckel G, Brickmann J: A new approach to analysis and display of local lipophilicity/hydrophilicity mapped on molecular surfaces. J Comput Aided Mol Des (1993) 7(5):503-514.
80. Jaeger R, Schmidt F, Schilling B, Brickmann J: Localization and quantification of hydrophobicity: The molecular free energy density (MolFESD) concept and its application to sweetness recognition. J Comput Aided Mol Des (2000) 14(7):631-646.
81. Zachmann CD, Kast SM, Brickmann J: Quantification and visualization of molecular surface flexibility. J Mol Graph (1995) 13(2):89-97.
82. Zachmann CD, Heiden M, Schlenkrich M, Brickmann J: Topological analysis of complex molecular surfaces. J Comp Chem (1992) 13(1):76-84.
83. Broughton HB: A method for including protein flexibility in protein-ligand docking: Improving tools for database mining and virtual screening. J Mol Graph Modelling (2000) 18(3):247-257. The author describes an elegant method for the inclusion of protein flexibility within virtual screening calculations. COX-2 inhibitors are used as examples, resulting in a good correlation to their biological activity.
84. Good A: Structure-based virtual screening protocols. Curr Opin Drug Discovery Dev (2001) 4(3):301-307. Recent review provides an excellent overview of the status of virtual screening methods.
85. Mukherjee D, Nissen SE, Topol EJ: Risk of cardiovascular events associated with selective COX-2 inhibitors. J Am Med Assoc (2001) 286(8):954-959.
86. MedWatch: Food and Drug Administration, Washington DC, WA, USA (2002). http://www.fda.gov/medwatch/SAFETY/2002/apr02.html#vioxx
87. Bing RJ, Lomnicka M: Why do cyclo-oxygenase-2 inhibitors cause cardiovascular events? J Am Coll Cardiol (2002) 39(3):521-522.
88. MERCK & CO INC (Bayly CI, McKeever BM, Ouellet M, Pandya SR, Percival MD, Roy P): Crystals of human cyclooxygenase-2 (hCOX-2). GB-02319032 (1998).
89. NOVARTIS AG (Becker K, Fujimoto RA, Mcquire LW, Mugrage BB, van Duzer JH, Xu D): Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives. WO-09911605 (1999).
90. SANKYO COMPANY LTD (Kimura, T, Noguchi Y, Nakao A, Suzuki K, Ushiyama S, Kawara A, Miyamoto M): 1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses. EP-00799823 (1997).